程序性死亡受体1单抗联合阿帕替尼治疗罕见原发性肝脏鳞状细胞癌1例报告

费语晨; 吕东来

doi:10.3969/j.issn.1001-5256.2021.03.032

程序性死亡受体1单抗联合阿帕替尼治疗罕见原发性肝脏鳞状细胞癌1例报告

DOI: 10.3969/j.issn.1001-5256.2021.03.032

费语晨^{1, 2},
吕东来^2, ,

1.
安徽医科大学解放军临床学院，合肥 230031
2.
解放军联勤保障部队第九〇一医院肿瘤科/安徽省肿瘤学临床重点专科实验室，合肥 230031

基金项目:

2018年安徽省自然科学基金面上项目 (1808085MH267);

安徽省重点研究与开发计划面上攻关项目 (202004a07020020)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：费语晨负责收集数据，整理资料，撰写论文；吕东来负责指导撰写，参与修改论文。

详细信息

作者简介:
费语晨(1997—)，女，主要从事实体肿瘤的诊疗研究

通信作者:
吕东来，lvxunhuan@163.com

中图分类号: R735.7
计量
- 文章访问数: 358
- HTML全文浏览量: 116
- PDF下载量: 28
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-06
- 录用日期: 2020-11-02
- 出版日期: 2021-03-20

Anti-PD-1 monoclonal antibody combined with apatinib in treatment of rare primary squamous cell carcinoma of the liver: A case report

Yuchen FEI^{1, 2},
Donglai LYU^{2
, ,}

1.
PLA Clinical College of Anhui Medical University, Hefei 230031, China
2.
Department of Oncology, The 901 Hospital of Joint Logistics Support Force of PLA/Anhui Key Clinical Specialty Laboratory of Oncology, Hefei 230031, China

摘要

- 肝肿瘤 /
- 癌，鳞状细胞 /
- 药物疗法
- Liver Neoplasms /
- Carcinoma, Squamous Cell /
- Drug Therapy

HTML全文

图 1 肝脏穿刺组织病理学检查结果

注：a, 肝内浸润性鳞状细胞癌(HE染色，×400); b, 免疫组化显示P63阳性(×400); c, 免疫组化显示P40阳性(×400); d, 免疫组化显示Ki-67约20%阳性(×400)。

下载: 全尺寸图片幻灯片

图 2 PET/CT检查

注：a, 肝左叶巨大肿瘤(箭头)伴肝内多发转移; b~c, 肝门部及腹膜后转移淋巴结(箭头); d, 右侧髂骨体溶骨性骨质破坏(箭头)。

下载: 全尺寸图片幻灯片

图 3 治疗前后影像学检查对比

下载: 全尺寸图片幻灯片

参考文献(16)

[1]	NAIK S, WARIS W, CARMOSINO L, et al. Primary squamous cell carcinoma of the liver[J]. J Gastrointestin Liver Dis, 2009, 18(4): 487-489.
[2]	ZHANG XF, DU ZQ, LIU XM, et al. Primary squamous cell carcinoma of liver: Case series and review of literatures[J]. Medicine (Baltimore), 2015, 94(28): e868. DOI: 10.1097/MD.0000000000000868
[3]	ZHAO R, ZHU K, WANG R, et al. Primary squamous cell carcinoma of the liver: A case report and review of the literature[J]. Oncol Lett, 2012, 4(6): 1163-1166. DOI: 10.3892/ol.2012.894
[4]	ZHU KL, LI DY, JIANG CB. Primary squamous cell carcinoma of the liver associated with hepatolithiasis: A case report[J]. World J Gastroenterol, 2012, 18(40): 5830-5832. DOI: 10.3748/wjg.v18.i40.5830
[5]	SPAGGIARI M, DI BENEDETTO F, BALLARIN R, et al. Primary squamous cell carcinoma of the liver associated with Caroli's disease: A case report[J]. Onkologie, 2011, 34(4): 193-195. DOI: 10.1159/000326999
[6]	WILSON JM, GROESCHL R, GEORGE B, et al. Ciliated hepatic cyst leading to squamous cell carcinoma of the liver - A case report and review of the literature[J]. Int J Surg Case Rep, 2013, 4(11): 972-975. DOI: 10.1016/j.ijscr.2013.07.030
[7]	HUANG Y, ZHANG ZX, ZHENG JL, et al. Analysis of a case of primary squamous cell carcinoma of liver[J]. Chin J Bases Clin Gen Surg, 2020, 27(1): 82-87. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL202001018.htm 黄阳, 张致熙, 郑金利, 等. 1例原发性肝脏鳞状细胞癌分析[J]. 中国普外基础与临床杂志, 2020, 27(1): 82-87. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL202001018.htm
[8]	BOSCOLO G, JIRILLO A, DA PIAN P. Complete remission of poorly differentiated squamous liver carcinoma after systemic chemotherapy and surgery. A case report[J]. Tumori, 2005, 91(1): 71-72. DOI: 10.1177/030089160509100113
[9]	KAJI R, SASAKI N, TATEISHI I, et al. A case report of primary hepatic squamous cell carcinoma that remarkably responded to low dose arterial injection of anti-cancer drugs[J]. Kurume Med J, 2003, 50(1-2): 71-75.
[10]	YANG X, SHI ZR. Research progress of PD-1 pathway related drugs in the treatment of primary liver cancer[J]. J Med Theor Pract, 2019, 32(22): 3612-3614. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YXLL201922014.htm 杨旭, 史政荣. PD-1通路相关药物在原发性肝癌治疗中的研究进展[J]. 医学理论与实践, 2019, 32(22): 3612-3614. https://www.cnki.com.cn/Article/CJFDTOTAL-YXLL201922014.htm
[11]	DONG YP, LI DG. Research progress of tumor immunotherapy and PD-1/PD-L1 inhibitors[J]. Int J Biomed Eng, 2018, 41(1): 72-77. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201816010.htm 董银萍, 李德冠. 肿瘤免疫治疗与PD-1/PD-L1抑制剂的研究进展[J]. 国际生物医学工程杂志, 2018, 41(1): 72-77. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201816010.htm
[12]	WANG MD, WU H, YANG T. Research progresses of primary liver cancer from 2017 annual meeting of Chinese Society of Clinical Oncology[J]. Chin J Dig Surg, 2017, 16(11): 1109-1112. (in Chinese) 王明达, 吴寒, 杨田. 2017年中国临床肿瘤学会年会原发性肝癌研究进展解析[J]. 中华消化外科杂志, 2017, 16(11): 1109-1112.
[13]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2
[14]	NAING A, MERIC-BERNSTAM F, STEPHEN B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers[J]. J Immunother Cancer, 2020, 8(1): e000347. DOI: 10.1136/jitc-2019-000347
[15]	TU Y, PENG F. Clinical research advances of apatinib in the treatment of malignancies[J]. Chin J Clin Oncol, 2016, 43(12): 545-548. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201612017.htm 涂艳, 彭枫. 阿帕替尼治疗恶性肿瘤的临床研究进展[J]. 中国肿瘤临床, 2016, 43(12): 545-548. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201612017.htm
[16]	ZHAO S, REN S, JIANG T, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer[J]. Cancer Immunol Res, 2019, 7(4): 630-643. http://www.researchgate.net/publication/331055343_Low-Dose_Apatinib_Optimizes_Tumor_Microenvironment_and_Potentiates_Antitumor_Effect_of_PD-1PD-L1_Blockade_in_Lung_Cancer